Research Article| Volume 51, ISSUE 4, P482-488, March 2015

Download started.


Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer

Published:February 03, 2015DOI:



      Trastuzumab has been approved for use in combination with fluoropyrimidine plus cisplatin for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC). Although capecitabine plus oxaliplatin (XELOX) is a standard first-line regimen for AGC, combination trastuzumab plus XELOX has not been studied.


      Patients with metastatic or unresectable HER2-positive AGC were diagnosed by either HER2 immunohistochemistry (IHC) 3+ or IHC 2+/fluorescence in-situ hybridisation (FISH)+ received intravenous trastuzumab (8 mg/kg for first cycle and 6 mg/kg for subsequent cycles on day 1) plus oral capecitabine (1000 mg/m2 twice daily on days 1–14) and intravenous oxaliplatin (130 mg/m2 on day 1), every 3 weeks. The primary end-point was the objective response rate, and secondary end-points included progression-free survival (PFS), overall survival (OS) and toxicity profiles.


      Fifty-five HER2-positive AGC patients were enrolled between August 2011 and February 2013. The median age was 57 years (range = 29–74). The confirmed objective response rate was 67% (95% confidence interval (CI) = 54–80%). After a median follow-up period of 13.8 months (range = 6.1–23.9), the median PFS and OS were 9.8 months (95% CI = 7.0–12.6) and 21.0 months (95% CI = 6.4–35.7), respectively. Frequently encountered grade 3–4 toxicities included neutropenia (18%), anaemia (11%), and peripheral neuropathy (11%). There was a treatment-related death caused by severe diarrhoea and complicated sepsis.


      Combination of trastuzumab and XELOX is well tolerated and highly effective in patients with HER2-positive AGC.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jung K.-W.
        • Won Y.-J.
        • Kong H.-J.
        • Oh C.-M.
        • Lee D.H.
        • Lee J.S.
        Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2011.
        Cancer Res Treat. 2014; 46: 109-123
        • Shen L.
        • Shan Y.-S.
        • Hu H.-M.
        • Price T.J.
        • Sirohi B.
        • Yeh K.-H.
        • et al.
        Management of gastric cancer in Asia: resource-stratified guidelines.
        Lancet Oncol. 2013; 14: e535-e547
        • Gravalos C.
        • Jimeno A.
        HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target.
        Ann Oncol. 2008; 19: 1523-1529
        • Hofmann M.
        • Stoss O.
        • Shi D.
        • Büttner R.
        • van de Vijver M.
        • Kim W.
        • et al.
        Assessment of a HER2 scoring system for gastric cancer: results from a validation study.
        Histopathology. 2008; 52: 797-805
        • Boku N.
        HER2-positive gastric cancer.
        Gastric Cancer. 2013; 17: 1-12
        • Bang Y.-J.
        • Van Cutsem E.
        • Feyereislova A.
        • Chung H.C.
        • Shen L.
        • Sawaki A.
        • et al.
        Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
        Lancet. 2010; 376: 687-697
        • Kang Y.-K.
        • Yoon D.H.
        • Ryoo B.-Y.
        • Ryu M.-H.
        Recent advances in chemotherapy for advanced gastric cancer.
        APJOH. 2010; 2: 67-74
        • Kang Y.K.
        • Kang W.K.
        • Shin D.B.
        • Chen J.
        • Xiong J.
        • Wang J.
        • et al.
        Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.
        Ann Oncol. 2009; 20: 666-673
        • Cunningham D.
        • Starling N.
        • Rao S.
        • Iveson T.
        • Nicolson M.
        • Coxon F.
        • et al.
        Capecitabine and oxaliplatin for advanced esophagogastric cancer.
        N Engl J Med. 2008; 358: 36-46
        • Al-Batran S.E.
        • Hartmann J.T.
        • Probst S.
        • Schmalenberg H.
        • Hollerbach S.
        • Hofheinz R.
        • et al.
        Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the arbeitsgemeinschaft internistische onkologie.
        J Clin Oncol. 2008; 26: 1435-1442
        • Cunningham D.
        • Okines A.F.C.
        • Ashley S.
        Capecitabine and oxaliplatin for advanced esophagogastric cancer.
        N Engl J Med. 2010; 362: 858-859
        • Park Y.S.
        • Hwang H.S.
        • Park H.J.
        • Ryu M.-H.
        • Chang H.-M.
        • Yook J.H.
        • et al.
        Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use?.
        Hum Pathol. 2012; 43: 413-422
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        • Simon R.
        Optimal two-stage designs for phase II.
        Clinical Trials. 2002; : 1-10
        • Park Y.H.
        • Lee J.-L.
        • Ryoo B.-Y.
        • Ryu M.-H.
        • Yang S.H.
        • Kim B.S.
        • et al.
        Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer.
        Cancer Chemother Pharmacol. 2007; 61: 623-629
        • Dong N.
        • Jiang W.
        • Li H.
        • Liu Z.
        • Xu X.
        • Wang M.
        Triweekly oxaliplatin plus oral capecitabine as first-line chemotherapy in elderly patients with advanced gastric cancer.
        Am J Clin Oncol. 2009; 32: 559-563
        • Ding X.
        • Qu X.
        • Fan Y.
        • Che X.
        • Qu J.
        • Xu L.
        • et al.
        Trastuzumab and oxaliplatin exhibit a synergistic antitumor effect in HER2-postive gastric cancer cells.
        Anticancer Drugs. 2014; 25: 315-322
        • Starling N.
        • Rao S.
        • Cunningham D.
        • Iveson T.
        • Nicolson M.
        • Coxon F.
        • et al.
        Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK national cancer research institute upper gastrointestinal clinical studies group.
        J Clin Oncol. 2009; 27: 3786-3793

      Linked Article